{"disease":{"id":"cryopyrin-associated-periodic-syndrome","name":"Cryopyrin associated periodic syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"canakinumab","indication_name":"Cryopyrin associated periodic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ilaris","generic_name":"CANAKINUMAB","company_name":"Novartis Pharms","drug_phase":"marketed","molecular_target":"Interleukin-1 beta","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":59,"revenue":"1369","mechanism":""},{"drug_id":"rilonacept","indication_name":"Cryopyrin associated periodic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arcalyst","generic_name":"RILONACEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Interleukin-1 beta","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Arcalyst works by binding to Interleukin-1 beta, preventing its interaction with its receptor and reducing inflammation."},{"drug_id":"kineret","indication_name":"Cryopyrin associated periodic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anakinra","generic_name":"Kineret","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor, type I","drug_class":"Interleukin-1 Receptor Antagonist","quality_score":41,"revenue":null,"mechanism":""},{"drug_id":"anakinra","indication_name":"Cryopyrin associated periodic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kineret","generic_name":"ANAKINRA","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor, type I","drug_class":"Interleukin-1 Receptor Antagonist [EPC]","quality_score":70,"revenue":null,"mechanism":"Kineret blocks the action of interleukin-1, a protein that promotes inflammation."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02466217","title":"Phenomics in Autoimmune and Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":537,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04086602","title":"Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Inflazome UK Ltd","has_results":false},{"nct_id":"NCT04856540","title":"Adult Outcomes of Children With CAPS","phase":"","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT06974877","title":"Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06544018","title":"Circadian Rhythm Deregulation in Patients With CAPS","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06838143","title":"Ilaris NIS in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01576367","title":"Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02326376","title":"Kineret CAPS Post Authorisation Study","phase":"","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT05812781","title":"A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Zomagen Biosciences Ltd.","has_results":false},{"nct_id":"NCT05186051","title":"A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Zydus Lifesciences Limited","has_results":false},{"nct_id":"NCT04524858","title":"Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Aclaris Therapeutics, Inc.","has_results":true}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}